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Abstract
Mineral and bone disorder in chronic kidney disease (CKD-MBD) is a triad of biochemical imbalances of calcium, phosphate,
parathyroid hormone and vitamin D, bone abnormalities and soft tissue calcification.Maintaining optimal bone health in children
with CKD is important to prevent long-term complications, such as fractures, to optimise growth and possibly also to prevent
extra-osseous calcification, especially vascular calcification. In this review, we discuss normal bone mineralisation, the patho-
physiology of dysregulated homeostasis leading to mineralisation defects in CKD and its clinical consequences. Bone
mineralisation is best assessed on bone histology and histomorphometry, but given the rarity with which this is performed, we
present an overview of the tools available to clinicians to assess bone mineral density, including serum biomarkers and imaging
such as dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. We discuss key studies that have
used these techniques, their advantages and disadvantages in childhood CKD and their relationship to biomarkers and bone
histomorphometry. Finally, we present recommendations from relevant guidelines—Kidney Disease Improving Global
Outcomes and the International Society of Clinical Densitometry—on the use of imaging, biomarkers and bone biopsy in
assessing bone mineral density. Given low-level evidence from most paediatric studies, bone imaging and histology remain
largely research tools, and current clinical management is guided by serum calcium, phosphate, PTH, vitamin D and alkaline
phosphatase levels only.
Keywords Chronickidneydisease (CKD) .Dual-energyX-rayabsorptiometry(DXA) .PeripheralquantitativeCT(pQCT) .Bone
biopsy . Bonemineralisation
Introduction
There is a growing awareness that mineral dysregulation in
chronic kidney disease (CKD) is closely linked to abnormal
bone pathology, and that this in turn, may potentially lead to
extra-skeletal calcification. The KDIGO (Kidney Disease
Improving Global Outcomes) have proposed the broad and
encompassing term chronic kidney disease-mineral and bone
disorder (CKD-MBD) to describe this clinical entity [1]. MBD
is the triad of biochemical abnormalities (of calcium, phos-
phate, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin
D), bone abnormalities (short stature, reduced mineralisation
and increased risk of fractures) and extra-skeletal calcification
[2, 3]. Mineral dysregulation, leading to bone demineralisation,
plays a causal role in increased bone pain, deformities and
fracture risk in childhood CKD [4, 5].
Assessing bone health should be a key element in the clin-
ical assessment of children with CKD, but the tools available
to clinicians are not well researched and have many shortcom-
ings. A detailed assessment of bone health and bone
mineralisation in particular requires a combination of bio-
chemical measures, imaging techniques and in some in-
stances, bone biopsy. However, serum biomarkers may not
be reflective of the true state of bone turnover or
mineralisation and imaging techniques have several
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limitations and are not widely available. Bone biopsies are
considered to be highly invasive and rarely performed in
children.
In this review, we focus on the techniques available to the
clinician to assess bone mineralisation by imaging methods,
histology and biomarker studies. We examine their utility in
the clinical setting and discuss relevant recommendations
from international guidelines. Although bone mineralisation
is best assessed by bone histomorphometry [6, 7], radiological
techniques are also used to assess bone mineral density
(BMD) as a proxy in clinical practice and some studies.
Given the low level of evidence from most clinical studies,
these techniques are largely reserved for research, and current
clinical management is guided by serum calcium, phosphate,
PTH, vitamin D and alkaline phosphatase levels only.
Normal bone mineralisation in the growing
skeleton
Bone development involves a process of organic matrix for-
mation (osteoid), that is mineralised to form bone, and finally
undergoes remodelling by resorption and reformation, old
bone being replaced continuously by new bone (Figs. 1a and
b) [8, 9]. Remodelling of bone is controlled by osteoblasts and
osteoclasts. Osteoblasts secrete procollagen during bone for-
mation, and the end peptides are cleaved off during matrix
formation to produce type 1 collagen. This structure serves
as a scaffold around which mineralisation occurs [10].
Phosphates are released locally from the matrix vesicles in
the osteoid. Calcium from the extracellular compartment then
forms hydroxyapatite with the phosphates [11]. These crystals
are also comprised of small amounts of sodium, magnesium
and carbonate [12]. When the newly formed crystals are no
longer soluble, they deposit in the form of hydroxyapatite in
the vesicles. If there is sufficient phosphate and calcium avail-
able, hydroxyapatite formation continues to fill the spaces
between the collagen fibres [13]. New bone formation hap-
pens by modelling and longitudinal growth at the growth
plates by chondrocytes which are located between the epiph-
yses and metaphyses of long bones. The growth plates grad-
ually move further away from the bone centre, producing
elongation of the bone [14, 15]. Growth hormone is key in
this process by driving the differentiation of chondrocytes to
osteogenic cells, increasing cellular proliferation, increasing
insulin-like growth factor 1 (IGF1) that stimulates the expan-
sion of the chondrocytes and increasing deposition of type 1
collagen leading to further bone growth [14].
Bone mass, on the other hand, depends on the balance
between bone resorption and formation. Bone modelling pro-
duces growth of the skeleton and changes in bone shape in
response to mechanical forces [16]. This is the predominant
driving force in early life. Remodelling renews bone and
maintains mineral homeostasis. It repairs bone damage by
resorbing old bone and forming new bone. In the growing
skeleton, remodelling occurs very rapidly with a positive bal-
ance to account for mineral deposition and skeletal growth
[17, 18]. Both phases of bone metabolism—modelling and
remodelling—are crucial in order to maintain good bone
strength and prevent fractures.
Calcium requirements for normal bone
mineralisation
Peak bone mass (PBM) is defined as ‘the amount of bone
gained by the time a stable skeletal steady state has been
attained during adulthood’ [19]. This incorporates and in-
fluences bone strength, which is derived from the structural
properties provided by mass, density, microarchitecture
and geometry of the bone. In a prospective study of 125
healthy girls over 8 years, girls who sustained at least one
fracture (n = 42, cumulative incidence 46.6%) were more
likely to have lower bone mass by DXA [20]. The US
National Osteoporosis Foundation position statement on
peak bone mass development gives high-level evidence
for physical activity and calcium intake on bone accretion,
especially during late childhood and peripubertal years
[19]. Normal bone mass accrual during growth is extreme-
ly important in preventing fractures in later life [19]. This
is not surprising given that the mineral composition of
bone accounts for two-thirds of its dry weight [12].
The timing of PBM accrual varies between the sexes
and by the skeletal site. The Saskatchewan Paediatric
Bone Mineral Accrual Study followed 164 children aged
8–14 years into their early 30s with dietary information
and whole body DXA scans [21, 22]. They showed that
peak height velocity (PHV) was reached by 11.8 and
13.5 years for females and males, respectively, but PBM
(highest BMC by total body DXA) was attained 7 years
later. Bone development in terms of growth and length
stopped around 5 years after PHV, followed by a plateau
of bone mineralisation 2 years later (18.8 and 20.5 years
for females and males respectively). However, at the lum-
bar spine and hips, in particular, PBM was achieved
5 years after PHV [22]. Previous cross-sectional studies
had suggested that PBM is achieved even later than this.
Recker et al. showed that in 156 healthy adult women, the
mineral accrual stopped by 28.3 to 29.5 years of age [23].
Lin et al., studying 300 healthy females aged 6 to
32 years, found that bone mineral content (BMC) was
highest in this cohort in the early twenties (23.0 ±
1.4 years), but increases in BMC were seen into the early
thirties [24]. In summary, approximately 25% of PBM is
formed around the 2-year interval of PHV which happens
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in adolescence, but PBM is likely achieved by the end of
the second or early third decade of life [22].
More than 99% of the calcium in the body is stored in
the skeleton. The calcium content of the skeleton in-
creases from 25 g at birth to around 1000 g in adulthood.
This is the reason why the growing skeleton of children
has a higher demand for calcium compared to adults [25].
Adequate dietary calcium intake during childhood and
puberty is necessary for skeletal development and for
attaining peak bone mass. Matkovic et al. published an
aggregated report of 519 calcium balance studies per-
formed on participants from birth to 30 years old. In every
age group, calcium balance positively correlated with cal-
cium intake from diet or supplements. The highest calci-
um requirement was in the first year of life (503 ± 91 mg/
day) and during pubertal growth (396 ± 164 mg/day),
dropping thereafter to normal adult requirements (114 ±
133 mg/day) [25]. This implies higher intestinal calcium
Fig. 1 aRemodelling of bone is controlled by osteoblasts and osteoclasts.
Bone formation happens through organic matrix formation (osteoid), that
gets mineralised to form bone, and finally undergoes remodelling by
resorption and reformation. Calcium and phosphate form
hydroxyapatite that deposits in the extracellular compartment, between
collagen fibres. Osteoclasts are responsible for bone resorption, removing
bone minerals and matrix. Certain biochemical markers reflect bone
turnover and bone cell activity. Bone regulators can be grouped broadly
into bone turnover factors (e.g. PTH, sclerostin) and bone cell activity
indicators (bone formation, e.g. bone-specific alkaline phosphatase
(BSAP), osteocalcin (OC), procollagen type I N propeptide (PINP),
procollagen type I C propeptide (PICP); bone resorption, e.g.
carboxyterminal cross-linking telopeptide of bone collagen (CTX),
tartrate-resistant acid phosphatase (TRAP5b)). b Bone resorption is acti-
vated by the RANK-RANKL-OPG pathway, which regulates osteoclast
differentiation and activation. Osteoclast precursors express RANK,
which is activated by its ligand, RANKL, produced by osteoblasts and
osteocytes. Osteoprotegerin (OPG), also a product of osteoblasts and
osteocytes, is a decoy receptor for RANKL, neutralising the osteoclastic
function activated by the RANKL-RANK complex. Thus, the RANKL/
OPG ratio is an important determinant of bone mass as it affects
mineralisation, alkaline phosphatase, Runx2 and osteocalcin which re-
flect osteoblast differentiation and bone formation rate. Figure adapted
from Charoenphandhu et al. [117]
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absorption and uptake by the growing skeleton in child-
hood and adolescence [25].
Studies have also associated oral dietary calcium intake
with bone growth and mineral accrual in childhood [26,
27]. Bonjour et al. showed that daily consumption of a
high calcium intake led to a greater increase in radial and
femoral BMD in pre-pubescent girls [28]. Similarly,
Cadogan et al. demonstrated that an increased intake of
calcium (through milk) over 18 months resulted in a sig-
nificant increase in BMD (9.6% vs 8.5%, p = 0.017) and
BMC (27.0% vs 24.1%, p = 0.009) by DXA in 82 12-
year-old girls [29]. A randomised trial of 354 adolescent
girls showed that increased calcium intake translated into
significantly higher radial and total body BMD on DXA
scan over the 7-year follow-up [30]. Abrams et al. using a
calcium isotope technique demonstrated that increased di-
etary calcium absorption was the main driver of net cal-
cium retention in infants and adolescents [31, 32]. The
higher calcium requirements in children are also reflected
in higher normal values for serum total calcium in chil-
dren, particularly during periods of active growth in in-
fancy, and reach adult levels by 5 years of age. The (US)
National Osteoporosis Foundation’s position statement re-
view found that 90% of randomised control trials using
calcium supplement pills showed a statistically significant
effect on BMD and/or BMC accrual. This was especially
seen in children with a lower calcium intake at baseline
[19]. As bone mineral accrual in infancy, childhood and
adolescence is closely linked with calcium intake and par-
ticularly oral calcium absorption [26, 27], any condition
which disrupts this mechanism may lead to poor
mineralisation [19].
Abnormal bone mineralisation in CKD
As the glomerular filtration rate reduces, phosphate excretion
is impaired [33]. The reduced 1-alpha-hydroxylation of 25-
hydroxyvitamin D from the failing kidneys leads to reduced
intestinal absorption of calcium and results in hypocalcaemia.
Hypocalcaemia stimulates increased PTH production by the
parathyroid glands and elevated phosphate levels stimulate
fibroblast growth factor 23 (FGF23) secretion by osteocytes
(Fig. 2) [34–36]. These compensatory pathways aim to in-
crease phosphaturia and mobilise calcium out of its reservoir
in the bone. PTH causes increased phosphaturia by acting on
the renal phosphate sodium co-transporter and increases bone
resorption [37], releasing calcium, which affects overall bone
mineralisation [38–40]. FGF23 may also directly inhibit Wnt
signalling pathways which are needed in bone mineralisation
[41]. This high resorption state and demineralisation leads to
an overall degradation of bone architecture, decreased BMD
and increased fracture risk [10, 42].
The burden of MBD in childhood CKD
and the resulting fracture risk
Chronic kidney disease affects bonemodelling, remodelling and
growth. Poorly controlled CKD leads to reduced bone mass
accrual and accelerated bone loss. These alterations occur early
in the course of CKD [43] but the entire and complete processes
by which these abnormalities of skeletal mineralisation occur
are not entirely clear [44]. Bone strength is determined by the
bone mass and bone quality. It is affected by many factors in-
cluding sex hormones, BMD, microarchitectural organisation,
geometry and size. Cortical thickness and mineralisation are
major contributors to overall bone strength [45, 46]. CKD in
childhood affects mineral homeostasis and the normal process
of mineral accrual and deposition in the bone, thereby affecting
bone mass, architecture and strength [2, 15].
Children with CKD are reported to have bone pain, limb
deformities, short stature and a three-fold higher fracture inci-
dence compared to their healthy peers [43, 47]. Borzych et al.,
using the clinical registry of the International Paediatric
Fig. 2 In chronic kidney disease (CKD), hypocalcaemia, low 1,25 OH
vitamin D levels and hyperphosphataemia develop. In an attempt to
increase phosphaturia, and thus decrease serum phosphate levels,
FGF23 production increases. Raised FGF23 may directly inhibit Wnt
signalling pathways which are needed in bone mineralisation. Low
1,25OHVitD and low serum calcium lead to increased PTH production.
This in turn causes increased bone turnover with the aim of restoring
normocalcaemia, by mobilising calcium out of bone. The reduced
production of active vitamin D from the kidneys perpetuates
hypocalcaemia further fuelling this cycle. This demineralisation affects
bone quality as a whole leading to an increased risk of fractures and
decreased bone strength
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Peritoneal Dialysis Network (IPPN), showed that clinical
symptoms or radiological signs of bone disease were present
in 15% of 890 children and adolescents. These included ra-
diological signs of renal rickets and osteopenia but also limb
deformities and pain [33]. Fifty percent of children with CKD
will not attain their genetically pre-determined height and re-
main significantly shorter [48].
The CKiD study (CKD in Children) has recently evaluated
the burden of fractures in a large cohort of children. The re-
ported fracture rates of 395/10,000 person-years for males and
323/10,000 person-years for females were 2.4- and 3-fold
higher, respectively, than gender-specific rates of 162/10,000
person-years and 103/10,000 person-years reported in a large
population-based study of fracture epidemiology in healthy
children and adolescents [38], and exceeding those reported
in over 12,000 adult haemodialysis patients [38, 49]. The in-
dependently linked factors to higher fracture rates were base-
line walking difficulty, Tanner stages of pubertal development
4–5, greater height Z-score, higher PTH levels and competi-
tive sports participation. The only possible protective factor
was phosphate binder use which afforded a 63% lower frac-
ture risk; of note, 82% of patients in this study were on
calcium-based phosphate binders, suggesting that improved
phosphate control or the calcium absorption from the binder
may afford some protective benefit [38, 43].
Lower BMD measured by peripheral quantitative comput-
ed tomography (pQCT) was identified as a significant predic-
tor of fracture risk in a study of 170 children and young people
up to 21 years old in CKD stages 2–5 and on dialysis. Lower
serum calcium levels were independently associatedwith low-
er cortical volumetric BMD Z-scores. Over a 1-year follow-up
in 89 children, a change in the cortical BMD Z-score positive-
ly correlated with baseline calcium (p = 0.008) and increase in
calcium (p = 0.002) levels, particularly in growing children.
Of these participants, 6.5% suffered some form of fracture
during the study’s 1-year follow-up (incidence 556/10,000
person-years). Notably, lower cortical BMD Z-score predicted
future fractures: the hazard ratio for fractures was 1.75 (95%
CI 1.15–2.67; p = 0.009) per SD decrease in baseline BMD.
The fracture sites were the clavicle, tibia, foot, toes and radius.
These fractures were sustained in low-impact traumas, such as
exercise and falls. Independent risk factors attributed to frac-
ture risk were any period of rapid growth in adolescence,
lower calcium and vitamin D (25(OH)D) levels as well as a
higher PTH at baseline. All were associated with lower corti-
cal BMD scores [43].
The cumulative burden of MBD that develops during the
pre-transplant period may be further exacerbated after trans-
plantation. Children who have received any solid-organ trans-
plant had a 6-fold higher incidence of fractures overall, but
particularly vertebral fractures (160-fold) compared to healthy
peers in a 5-year follow-up period [50, 51]. Interestingly, a
reduced lumbar BMD Z-score was observed in 17% of the
par t ic ipants at the t ime of t ransplantat ion [51] .
Abnormalities in mineral metabolism also persist after trans-
plantation; in a registry study of 1237 European children, 19%
had hypocalcaemia and 40% had a high PTH 3 years after
transplantation (interquartile range 1.1–6.2 years) [50].
Mineral and bone disorder in childhood has long-lasting
consequences into adulthood. A study of 249 young adults
with the onset of end-stage renal failure pre-adolescence and
followed into adulthood showed that 37% had symptoms of
bone disease (deformities, bone pain, aseptic bone necrosis
and atraumatic fractures), 18% were disabled by bone disease
and 61% had severe growth restriction [47, 52]. The United
States Renal Data System reports that the relative risk of hip
fracture was highest in young adults (< 45 years old) on
haemodialysis, and hip fractures were associated with a more
than 4-fold increase in mortality in dialysis patients compared
to healthy age-matched peers [53–55].
Techniques for assessing bone health
Assessing bone health with a view to predicting and
preventing fractures in children with CKD is challenging.
Examining bone turnover, density and mineralisation in a
non-invasive way that does not involve radiation are not pos-
sible. The current tools available for assessing bone turnover
and density include bone histomorphometry, blood bio-
markers and imaging techniques. We discuss these in turn.
Bone biopsy
Bone biopsy is considered the gold standard for bone assess-
ment and allows assessment of the dynamic process of bone
formation and resorption. The histologic findings are
categorised in terms of bone turnover, mineralisation and vol-
ume (the ‘TMV’ classification) [56]. Bone biopsy is an inva-
sive procedure and only a handful of adult and paediatric
nephrology centres around the world perform this in clinical
practice or for research purposes. The procedure requires an
anaesthetic and dosing with tetracycline, which has UV fluo-
rescence properties, at two different time intervals to ‘label’
the bone for assessment of the dynamic features of bone for-
mation [57].
A review of five bone biopsy studies, performed in a total
of 172 children on HD or PD, showed that 14–37% showed
normal bone histology, with 22–43% showing low bone turn-
over. High PTH levels were able to identify high bone turn-
over states, but lower PTH levels were not able to distinguish
between low and normal bone turnover [58]. A detailed dis-
cussion of bone histomorphometry studies and correlations
with biomarkers is presented in the section below.
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Serum biomarkers of bone formation and resorption
Regulators of bone mineralisation and turnover can be mea-
sured in the blood or urine and reflect the metabolic activity of
bone cells (Fig. 1b). They are usually grouped into:
i. Bone formation markers: Bone-specific alkaline phospha-
tase (BSAP), osteocalcin (OC), procollagen type I N
propeptide (PINP), procollagen type I C propeptide
(PICP). These markers are products of osteoblast metabo-
lism and activity and reflect the production of type 1 col-
lagen, the structure that serves as a scaffold around which
mineralisation occurs [10], and accounts for more than
90% of the organic component of the bone matrix [12].
BSAP reflects bone formation rate [59]. In healthy chil-
dren, BSAP is associated with age, and gender [60], in-
creasing at the start of puberty, associated with height ve-
locity and higher in boys [60].
ii. Bone resorption markers: Carboxyterminal cross-linking
telopeptide of bone collagen (CTX) and tartrate-resistant
acid phosphatase (TRAP5b). These markers are mainly
by-products of type 1 collagen breakdown [10].
iii. Osteocytic markers: Phosphate-regulating gene with ho-
mologies to endopeptidases on the X chromosome
(PHEX), dentin matrix protein-1 (DMP1), matrix extra-
cellular phospho-glycoprotein (MEPE), sclerostin and
FGF23 that can regulate both osteoblastic and osteoclas-
tic activity [61].
All these biomarkers have been researched, drawing
correlations with bone histology, imaging and fracture
outcomes, but only PTH and BSAP are considered useful
adjuncts to calcium and phosphate measurements in clin-
ical practice.
In bone histomorphometry studies, serum PTH has been
associated with both bone mineralisation and turnover
(Table 1). However, PTH can remain within normal levels in
the early stages of CKD, despite bone biopsy studies showing
that almost a third of children in CKD stage 2 have poor bone
mineralisation [62, 63]. In 2010, Bakkaloglu et al. reviewed
bone biopsies of 161 children on PD and identified
mineralisation abnormalities in 48% of all patients.
Abnormal mineralisation was found in 58% of participants
with high bone turnover, 38% with normal turnover and
29% with low turnover. Serum PTH and alkaline phosphatase
correlated with bone turnover (PTH: r = 0.61, p < 0.01; alka-
line phosphatase: r = 0.51, p < 0.01) and serum calcium was
inversely related to mineralisation (p < 0.01) but not bone
turnover. In any turnover state, higher PTH values and lower
calcium values associated with abnormal mineralisation [62].
The authors demonstrated that when both PTH and alkaline
phosphatase levels were within 2xULN normal bone turnover
and normal mineralisation was seen [62].
Furthermore, PTH does not discriminate effectively be-
tween low- and high-turnover bone disease, in the ranges
where most patients’ PTH values are found (100–1000 ng/
L) [64]. Salusky et al., looking at biopsies of 55 children,
found that serum calcium levels were higher in patients with
adynamic bone or normal bone than in those with high PTH
values. On the other hand, serum phosphate, alkaline phos-
phatase and PTH levels were higher in patients with osteitis
fibrosa. The combination of a high serum PTH and normal
calcium value was 85% sensitive and 100% specific for iden-
tifying patients with the high-turnover bone disease [65]. In
general, all high-turnover disease was associated with high
PTH levels (> 3 ULN upper limit normal) whereas adynamic
bone disease and normal bone turnover were associated with
lower PTH values, but the ability of PTH to distinguish be-
tween the two is not strong.
On clinical correlations, maintaining PTH within normal
levels up to 2× ULN was associated with good growth [66].
In a study of 556 children aged 6–18 years with CKD (eGFR
10–60 mL/min/1.73 m2), BSAP SDS values decreased with
declining eGFR and closely associated with PTH [67]. In
patients treated with growth hormone, BSAP showed an in-
crease after treatment. BSAP SDS were predictive of a pro-
spective change in height SDS [67]. The International
Paediatric Peritoneal Dialysis Network Registry that followed
up nearly 900 children on PD found that clinical and radio-
logical symptoms markedly increased when PTH exceeded
300 pg/mL, the risk of hypercalcemia increased with levels
below 100 pg/mL and time-averaged PTH concentrations
above 500 pg/mL were associated with impaired longitudinal
growth [33]. In a prospective study of 171 children with CKD,
high PTH was independently associated with a decline in tib-
ial cortical BMD on annual follow-up. [43]. A further study
has also correlated higher BSAP and CTX levels were asso-
ciated with lower cortical BMD [68].
In summary, no biomarker, individually or in combination,
is sufficiently robust to diagnose bone mineralisation or turn-
over defects [69, 70]. Furthermore, biomarkers vary depend-
ing on age, gender, pubertal stage, fasting status and circadian
rhythms and assays are not always standardised [60, 71].
Larger paediatric studies that correlate bone biomarkers with
the gold standard of bone histomorphometry as well as
patient-level outcomes such as fractures are required.
3. Imaging techniques
Dual-energy X-ray absorptiometry
DXA is a tool that is used for evaluating bone density and
assessing fracture risk in children and in adults. There is a
growing body of literature on the use of DXA in different
paediatric diseases [72].
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Principle A DXA scanner produces X-rays at 2 different en-
ergies, enabling the differentiation of soft tissue and bone [73].
Even at low levels of radiation (4–27 μSv) [74], DXA allows
for measurement of bone mineral content (BMC) and
projected bone area (BA), from which the areal BMD is cal-
culated as BMC/BA.
TechniqueMeasurements can be made at the spine, hip, fore-
arm or whole body (WB, also described as the total body
(TB)) [73]. Common sites in paediatric practice include lum-
bar spine (LS) and total body less head (TBLH) [75]. In chil-
dren, LS DXA is particularly useful because vertebrae are
mainly trabecular bone, and this site is readily influenced by
pathologic processes, due to the rapid bone turnover [72]. The
L1 to L4 region is recommended in the posterior-anterior di-
rection. In adults, the recommended site is the femoral neck,
as any possible aortic calcification can hinder interpretation of
the lumbar region. Changes with growth and variations in
development limit the use of the femoral site in pre-pubertal
children. Good positioning of the patient by the operator is
vital, but subsequently scanning lasts only a few seconds.
Imaging can be blurred by motion artefact in very mobile
children [76].
Information obtained DXA gives information on BMC
(Table 2), measured in grams (g). This is produced automati-
cally by the software and can be normalised for the child’s
height or bone area. BMD and content of mineral in a
projected area of bone (g/cm2) are automatically derived and
expressed in age, sex and ethnicity matched Z-scores [77]. If
the score is below 2 standard deviation points (− 2 SD), then it
indicates an abnormally low BMD for age [75]. Importantly,
BMD reflects density in a two-dimensional projection only.
Therefore, it may be misleading in shorter children or those
with delayed growth, as the projected bone area will be small-
er. To overcome this problem, bone mineral apparent density
(BMAD) is used to try and estimate the whole bone density in
gram per cubic centimetre. A Z-score is also the preferred
comparator for this measure (Fig. 3a and b).
Reference data in healthy children Reference data for lumbar
spine (L1-L4) BMAD and areal bone mineral density (areal
BMD) in healthy children are available from 3598 healthy 4 to
20 year olds from 7 UK centres [78]. Studies providing refer-
ence curves from other datasets, mainly from the USA also
exist [79–82]. DXA results should be adjusted for bone size
(i.e. growth of the child), consistent with the 2013
International Society of Clinical Densitometry (ISCD)
Paediatric official positions [76]. Equations to adjust DXA
results for height Z-score are available [83]
Relative advantages and disadvantages Table 3 lists the
main advantages and shortcomings of DXA in children.
The greatest drawback of the DXA technique is that it
assesses a three-dimensional structure (e.g. spinal vertebral
body) as a two-dimensional image. Trabecular and cortical
bone are superimposed, so studying the trabecular and cor-
tical BMD separately cannot be done. Given that DXA
measures areal BMD (g/cm2), it can underestimate volu-
metric BMD (g/cm3) in children with short stature [83] and
overestimate BMD in a tall child [73]. Therefore, it is vital
Z-scores are adjusted for poor growth especially in CKD
[84]. Serial DXA scanning in growing children can be par-
ticularly challenging.
Table 2 Important terminology used when assessing bone. The
terminology used when assessing bone. Important distinctions are made
between BMC and BMD. The definitions of areal BMD and BMAD
ensure that the limitations of DXA scanning in growth-stunted children
with CKD are accounted for
Terminology Definition, units and description
Bone mineral content (BMC) The amount of mineral found in an area of bone. Calcium is the predominant mineral found in bone.
Measured in grams (g)
Bone mineral density (BMD) Mass of mineral per unit volume of bone
This reflects the ratio of bone mass to bone volume.
Referred to as cortBMD for the bone cortex and trabBMD for the trabecular bone
The ratio of BMC over bone size and thus expressed in g/cm3.
BMD has been used interchangeably with areal BMD in the literature.
Areal bone mineral density
(areal BMD)
A term used within DXA reporting.
Mineral mass of the bone, divided by projection area of the X-rays (BMC/BA). The commonest parameter used in
assessing bone.
Represents a composite of bone size and mass
Expressed in g/cm2
Bone mineral apparent density
(BMAD)
BMAD is obtained by dividing the BMC by the estimated three-dimensional bone volume derived from its two
dimensional projected bone area.
This is done in children to account for growth and size in assessing bone density.
For example, the lumbar spine is assumed to be of cylindrical or cuboidal shape in children when calculating BMAD.
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Fig. 3 a DXA images. This is an example of DXA imaging of the L1-4
spine of a 16-year-old male with chronic kidney disease. His mean L1-4
age-matched Z-score is − 2.2. However, when adjusted for his shorter
height and poor growth, his BMAD Z-score is − 0.8 (the BMAD value
is obtained by adding the bonemineral content of the L1-L4 vertebrae and
dividing by the total volume of the 4 vertebrae). b This is an example of a
DXA image of both hips of a 14-year-old girl with chronic kidney disease
on home nocturnal haemodialysis. Her mean age-matched Z-score for
both hips is − 2.5
Pediatr Nephrol
Studies in CKD In adults with CKD, there is convincing evi-
dence that lower BMD by DXA indicates an increased frac-
ture risk. Yenchek et al. studied BMD by the femoral neck and
total hip DXA in 2754 older adult individuals and showed that
lower femoral neck BMD was associated with a higher frac-
ture risk regardless of CKD status (hazard ratio 2.69, 95%
confidence intervals 1.96–3.69) [85]. In a longitudinal study
by Iimori et al., adult participants with the lower total hip (p =
0.0006) or whole body (p = 0.006), BMD scores were more
likely to have new fractures [86]. Two further cross-sectional
studies by Nickolas et al. have shown associations between
hip BMD and fracture history in adults with CKD [87, 88].
There are a few notable studies that have used DXA to
determine BMD in the context of childhood CKD. Few
explore associations with mineral dysregulation and frac-
ture risk in children (Table 4). A study of 40 children both
with pre-dialysis CKD and on dialysis showed that all had
decreased BMD [89]. Waller et al. used lumbar DXA to
assess BMD in a paediatric cohort of 64 patients with
CKD, whilst studying biochemical markers and found that
maintaining normal calcium, phosphate and PTH concen-
trations was associated with normal lumbar BMD and
growth [90]. Griffin et al. used DXA and pQCT to assess
BMD in 88 children with CKD stages 4–5 and compared
the scores to 650 healthy participants aged 5–21 years old.
They demonstrated that adjusting for lower height Z-scores
in the CKD population results in increased BMD Z-scores
in the lumbar spine and whole body DXA scans. This ac-
counts for poor growth in this population, thereby avoiding
overestimation of bone deficits [84].
Importantly, a study in 56 children after renal transplanta-
tion used both DXA and tibial pQCT to determine fracture
risk [91] found that changes in DXA spine-BMD and tibial
pQCT trabecular BMD correlated (r = 0.47, p < 0.01) and
changes in whole-body BMC Z-scores were associated with
changes in tibia cortical area Z-scores (r = 0.52, p < 0.001), but
not changes in cortical BMD Z-scores. This suggests that the
theoretical limitations of DXA in determining cortical and
trabecular BMD may not be a major limitation in CKD pa-
tients after all.
Quantitative computed tomography
PrincipleQCT is a technique whereby CT images acquired are
analysed by specific software to obtain quantitative measures
such as volumetric bone mineral density (volumetric BMD)
and BMC in any bone compartment [92]. Other measures
acquired can be bone cross-sectional area or cortical thickness.
Whole body CT scanners can be used, as well as specifically
peripheral QCT scanners. The scanners used most commonly
are the XCT 2000 and 3000 scanners (StratecMedizintechnik,
Pforzheim, Germany). They use a rotate/translate technology
and can produce a 2D slice in around 1 min [74].
Technique pQCT has evolved from the quantitative CT tech-
niques in the 1970s and can now be done rapidly, accurately
and peripherally. pQCT provides volumetric and density data
in gram per cubic centimetre. It can distinguish between tra-
becular and cortical bone compartments independent of the
size of the subject [73]. Due to this differentiation and because
the trabecular bone is more metabolically active, pQCT offers
a unique perspective when studying and assessing bone.
Performing the scan requires the placement of a reference
line on an initial ‘scout view’ image of the distal portion of the
limb to be scanned; the software then selects the appropriate
slices longitudinally. The percentage distance from the refer-
ence line for the images is marked by the operator in a pre-set
program. This also relies heavily on the operator’s manual
measurement of length from the tibial plateau to the medial
malleolus in the lower limb, or from the head of the radius to
the styloid process in the upper limb. The reference line must
be placed correctly to avoid acquiring images at the growth
plates, growth arrest lines or bisphosphonate treatment lines,
as these can produce erroneous results (see Fig. 4a and b).
Reference data in healthy childrenReference data for children
is rather limited but published studies can be used to calculate
age-, height- and gender-matched Z-scores of the radius or
tibia [74]. There is, however, considerable heterogeneity in
the literature with regard to the location on a measured limb
Table 3 Advantages and
disadvantages of DXA imaging in
children. The main advantages
and disadvantages of DXA use in
assessing bone in childhood CKD
Advantages Disadvantages
Low radiation dose (4–27 μSv) Two-dimensional image—cannot distinguish
between cortical and trabecular bone
Evaluation of body composition is possible Assesses areal BMD in g/cm2, not density in
g/cm3
Operator independent—serial follow-up and
standardisation across sites possible
Underestimates BMD in children with poor
growth
Widely available Does not evaluate the microarchitecture of
bone
Reference data standardised for age, sex, race and height
adjusted standard deviation scores (SDS) available
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from which the images are obtained [93–98]. This must be
taken into account when choosing a reference database
Relative advantages and disadvantages Table 5 lists the main
advantages and shortcomings of pQCT in children. pQCT is
largely used in research practice only. The main drawback is
the marked heterogeneity in the literature in terms of reference
line placement, and where the most appropriate slice location
is on the tibia or radius for accurate and reproducible assess-
ments. (Anatomical measurement sites reported include 4%,
20%, 30% and 66% in the radius and 3%, 4%, 14%, 20%,
38% and 66% in the tibia from the distal end of the bone [74,
95]. This heterogeneity means there is a paucity of reference
data for age, height and puberty staging for comparison
[93–98].
Studies in children with CKD In childhood CKD, pQCT has
been used successfully to demonstrate the changes in bone
demineralisation seen as the disease progresses (Table 6).
A study comparing 156 children with CKD (stages 2 to 5
including 36 on dialysis) to 831 healthy participants (ages 5–
21 years) using tibial pQCT showed that iPTH levels above
the Kidney Disease Outcomes Quality Initiative (KDOQI)
recommended target was associated with increased trabecular
BMD Z-scores (p < 0.01), but lower cortical BMD scores
(p < 0.01). Cortical BMD Z-scores were significantly lower
in CKD stages 4–5 compared to healthy controls, and the
duration of CKD also affected this (p < 0.05) [68]. A greater
trabecular volumetric BMD was seen in younger participants,
the reason for which is not entirely clear. It is postulated that
this could be attributed to the anabolic effect of PTH, as this is
not seen in other chronic conditions [99]. Lima et al. showed
that in 21 patients on peritoneal dialysis, cortical BMD was
decreased and this correlated with higher alkaline phosphatase
and PTH levels. Trabecular BMD however was higher than in
controls, likely due to higher PTH [100]. As described previ-
ously, Denburg et al. have shown that per one SD lower base-
line cortical BMD Z-score, there was a 1.75-fold higher frac-
ture risk (95% CI 1.15–2.67, p = 0.009) in children with
CKD2-5D [43].
High-resolution pQCT
High-resolution pQCT (HRpQCT) uses a higher spatial
resolution allowing for an even more detailed look at the
trabecular bone microarchitecture and enabling measure-
ment of trabecular numbers, thickness and separation
[73]. Marques et al. have evaluated adult dialysis patients
that underwent bone biopsy and HRpQCT [101] and
showed that trabecular number, separation and thickness
obtained from HRpQCT and from bone biopsy correlated
and that patients with cort ical porosity on bone
histomorphometry presented lower cortical density at the
distal radius. However, HRpQCT could not predict
mineralisation abnormalities. Conversely, Pereira et al.
showed that bone mineralisation might be assessed by
HRpQCT in paediatric dialysis patients [102]. Ramalho
et al. obtained DXA imaging of the spine for a trabecular
bone score (TBS), and HRpQCT of the radius and tibia in
52 participants who had previously undergone bone biop-
sy. They showed that TBS ref lec ted t rabecular
microarchitecture as assessed by bone biopsy, and TBS
reflected cortical measures at the tibia as assessed by
HRpQCT [103]. Finally, Preka et al. assessed vascular
measures and HRpQCT in 32 children aged 10–17 years
with CKD stages 2–5 and found an association of calcium
and trabecular thickness with mean blood pressure [104].
Magnetic resonance imaging
Magnetic resonance imaging (MRI) and high-resolution MRI
(HR-MRI) in particular have recently been explored as a more
detailed way of non-invasively evaluating the bone structure,
without the use of ionising radiation [105]. In fact, it is thought
that it provides enough detailed information about the stan-
dard histomorphometry parameters and microarchitecture to
be considered a ‘virtual biopsy’ by some [106]. It allows for
detailed visualisation of both cortical and trabecular compart-
ments and making it possible to see actual three-dimensional
views of the architecture. The commonest sites used to obtain
images are the distal radius, calcaneus and distal tibia [107,
108]. Adult studies have compared MRI to bone
histomorphometry showing good correlation of studied indi-
ces across the two modalities [107, 109, 110]. There are no
studies in children with CKD.
Bone quantitative ultrasound
Quantitative ultrasound (QUS) has also been used to assess
bone as it is radiation-free, fast, inexpensive and readily avail-
able. The measurements are based on the attenuation of the
ultrasound wave or speed of sound as it passes through the
structure being examined. The penetration depth of the ultra-
sound waves means that only peripheral sites can be used:
commonly, the calcaneus, radius, phalanges or tibia are used.
In children, it is currently only used in research as an adjunct
to other modalities [111]. Adamczyk et al. assessed seventy-
six children with CKD and normal renal function who had
received glucocorticoid treatment by lumbar and total body
DXA as well as phalange QUS. The CKD group had the
lowest total body DXA Z-scores and the QUS Z-scores com-
pared to controls (p < 0.0001) [112]. Another study comparing
lumbar spine DXA and radius and tibia QUS in 643 partici-
pants aged 5–20 years old (412 healthy, 117 with cystic fibro-
sis and 114 with a body mass index kg/m2 above 95th centile)
showed a good correlation of the two modalities in healthy
Pediatr Nephrol
children. However, in children with cystic fibrosis or high
BMI, there was a 6–31% disagreement of measurements.
The authors concluded that the two modalities are not yet
interchangeable in their use or interpretation [113]. The pre-
dictive value of QUS for fracture risk is yet to be explored.
International guidelines on bone assessment
in childhood CKD-MBD
Current management of CKD-MBD is based on keeping cal-
cium, phosphate and PTH within an optimum range in order
to maintain bone turnover, but without increasing the risk of
ectopic calcification. This can be done by controlling plasma
calcium and phosphate by dietary restrictions, phosphate
binders, vitamin D, active vitamin D analogues and dialysis.
These are discussed in the 2006 European Paediatric Dialysis
Working Group (EPDWG) prevention and treatment of renal
osteodystrophy guidelines, the 2013 National Institute for
Health and Clinical Excellence (NICE) management of
hyperphosphataemia guidelines [114] and the 2017 KDIGO
CKD-MBD guidelines [3].
On biomarkers and bone biopsy in children
The bone biomarkers studied so far have not been sensi-
tive or specific enough to be translated into an accurate
clinical tool to predict bone turnover and mineralisation
states. The International Osteoporosis Foundation states
that bone turnover markers may be useful in routine clin-
ical practice to predict fracture risk and assess bone
mineralisation, but they currently have significant draw-
backs such as biological variability and inadequate evi-
dence [10]. It recommends studying PINP as the main
Table 5 Advantages and
disadvantages of pQCT imaging
in children. The main advantages
and disadvantages of pQCTuse in
assessing bone in childhood CKD
Advantages Disadvantages
Low radiation dose (< 1 μSV) Operator dependent on placing reference line
during scanning
Can distinguish between cortical and trabecular bone Not widely available, as mainly used in
research
Other measures acquired: cross-sectional bone area, cortical
thickness
Reference data heterogeneous and not
standardised
Volumetric density measured in g/cm3
Independent of patient size, so the height and weight of the
patient do not skew results
Fig. 4 a pQCT images. This is an example of pQCT imaging of the left
tibia of a 16-year-old male with chronic kidney disease. The images have
been obtained at 4 different sites along the tibia. The software then pro-
ceeds to automatic analysis of the bone parameters. In this example, the
images are from the 3%, 4%, 38% and 66% sites. b This is an example of
the analysis of the 38% site of the left tibia of a 16-year-old male with
chronic kidney disease. In this particular analysis, the total mass, total
area, cortical area and cortical density have been given
Pediatr Nephrol
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bone formation biomarker and CTX as the main bone
resorption biomarker to aid standardisation [10].
Although PTH and BSAP levels have been associated
with bone turnover, no biomarker is sufficiently robust to
diagnose low, normal and high bone turnover in an indi-
vidual patient. The 2017 KDIGO guidelines recommend
using trends in PTH rather than absolute ‘target’ values
when making decisions as to whether to start or stop
treatments to lower PTH. When trends in PTH are incon-
sistent, a bone biopsy may be considered. The recommen-
dation to perform a bone biopsy is based on the possibil-
ity it may affect treatment and the decision to administer
antiresorptive therapy. Since this is rarely, if ever, done in
children with CKD, the role of bone biopsies remains
questionable.
On bone imaging
The International Society for Clinical Densitometry
(ISCD) 2007 and KDIGO 2009 guidelines discouraged
routine DXA BMD testing in CKD3-5 since BMD does
not predict the type of bone turnover. This is because
hyperparathyroidism has generally catabolic effects on
the cortical bone with a decrease in cortical volumetric
BMD and cortical thickness whereas it exerts anabolic
effects on trabecular bone. However, the 2017 KDIGO
Guideline on treatment of CKD-MBD [3], based on four
prospective cohort studies of DXA BMD and incident
fractures in adults with CKD stages 3a to 5D [85, 86,
115, 116], demonstrated that DXA BMD predicted frac-
tures across the spectrum from CKD stages 3a to 5D in
adults. The guidelines therefore suggest that DXA BMD
assessment should be considered if it will lead to addi-
tional treatments or therapy recommendations in adults
[3, 85, 115].
For children with CKD, no studies have examined the
association between DXA results and fractures, and so the
KDIGO 2017 update does not provide specific recom-
mendations for DXA use in children. DXA has been sug-
gested as a potentially useful tool in assessing BMD in
children, given that good correlations have been shown
between DXA lumbar spine BMD and tibial pQCT mea-
sures [91], as well as the correlation between change in
tibial cortical BMD and fracture risk [43]. The ISCD in
their 2013 Official Positions document also suggests there
may yet be a role for DXA in the assessment of BMD in
children [76, 77]. Importantly, as children and adolescents
with CKD frequently exhibit substantial growth failure,
and DXA measures of areal BMD underestimate volumet-
ric BMD in children with short stature [83], DXA results
should be adjusted for bone size, consistent with the 2013
ISCD Paediatric Official Positions [76].
Conclusion
Skeletal abnormalities are prevalent in children with CKD,
affecting bone mineralisation from early CKD and manifest-
ing as bone pains, deformities and fractures. The bone disease
of childhood CKD can persist after transplantation and even
manifest with osteoporosis and fractures in adulthood. Bone
imaging, histology and biomarkers are variably used to assess
bone disease in CKD, but there are few evidence-based stud-
ies to promote their use in routine clinical practice. Current
clinical management, as advocated by the KDIGO 2017
guideline, is limited to the measurement and management of
trends in serum calcium, phosphate, PTH, vitamin D and al-
kaline phosphatase, with DXA assessment of BMD if it is
likely to influence clinical management.
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